Filippo Vit
Overview
Explore the profile of Filippo Vit including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
67
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Moia R, Talotta D, di Bergamo L, Almasri M, Dondolin R, Salehi M, et al.
Blood Adv
. 2025 Jan;
PMID: 39825831
Circulating tumor DNA (ctDNA) levels can help predict outcomes in diffuse large B-cell lymphoma (DLBCL), but its integration with DLBCL molecular clusters remains unexplored. Using the LymphGen tool in 77...
2.
Nabki J, Al Deeban B, Sium A, Cosentino C, Almasri M, Awikeh B, et al.
Leukemia
. 2024 Dec;
39(3):643-649.
PMID: 39690182
The mutational status of immunoglobulin (IG) light chain genes in chronic lymphocytic leukemia (CLL) and its clinical impact have not been extensively studied. To assess their prognostic significance, the IG...
3.
Bomben R, Zucchetto A, Laureana R, Chiarenza A, Olivieri J, Tissino E, et al.
Hemasphere
. 2024 Jul;
8(7):e128.
PMID: 39011128
No abstract available.
4.
Pozzo F, Forestieri G, Vit F, Ianna G, Tissino E, Bittolo T, et al.
Leukemia
. 2024 Jun;
38(8):1712-1721.
PMID: 38914716
The Bruton's tyrosine kinase (BTK) inhibitor ibrutinib represents an effective strategy for treatment of chronic lymphocytic leukemia (CLL), nevertheless about 30% of patients eventually undergo disease progression. Here we investigated...
5.
Mazzaro C, Visentini M, Gragnani L, Vit F, Tissino E, Pozzo F, et al.
Br J Haematol
. 2023 Jul;
203(2):237-243.
PMID: 37491625
We investigated 23 hepatitis C virus (HCV)-infected patients with overt lymphoproliferative diseases (15 cases) or monoclonal B lymphocytosis (8 cases) treated with direct agent antiviral (DAAs) per clinical practice. DAA...
6.
Bomben R, Rossi F, Vit F, Bittolo T, Zucchetto A, Papotti R, et al.
Leukemia
. 2023 Feb;
37(4):914-918.
PMID: 36807650
No abstract available.
7.
Leich E, Maier C, Bomben R, Vit F, Bosi A, Horn H, et al.
Blood Adv
. 2021 Oct;
5(23):4890-4900.
PMID: 34614504
We previously reported that t(14;18)-negative follicular lymphomas (FL) show a clear reduction of newly acquired N-glycosylation sites (NANGS) in immunoglobulin genes. We therefore aimed to investigate in-depth the occurrence of...
8.
Bomben R, Rossi F, Vit F, Bittolo T, DAgaro T, Zucchetto A, et al.
Clin Cancer Res
. 2021 Jul;
27(20):5566-5575.
PMID: 34285062
Purpose: In chronic lymphocytic leukemia (CLL), mutations are associated with reduced survival and resistance to standard chemoimmunotherapy (CIT). Nevertheless, the clinical impact of subclonal mutations below 10% to 15% variant...
9.
Viotto D, Russo F, Anania I, Segatto I, Rampioni Vinciguerra G, DallAcqua A, et al.
J Pathol
. 2020 Nov;
253(2):234-245.
PMID: 33140857
The CDKN1B gene, encoding for the CDK inhibitor p27 , is mutated in defined human cancer subtypes, including breast, prostate carcinomas and small intestine neuroendocrine tumors. Lessons learned from small...
10.
Pozzo F, Bittolo T, Tissino E, Vit F, Vendramini E, Laurenti L, et al.
Haematologica
. 2020 Oct;
106(12):3125-3135.
PMID: 33121237
Chronic lymphocytic leukemia (CLL) is characterized by a low CD20 expression, in part explained by an epigenetic-driven downregulation triggered by mutations of the NOTCH1 gene. In the present study, by...